home / stock / athe / athe news

ATHE News and Press, Alterity Therapeutics Limited

Stock Information
Company Name: Alterity Therapeutics Limited
Stock Symbol: ATHE
Market: NYSE
Menu
ATHE ATHE Quote ATHE Short ATHE News ATHE Articles ATHE Message Board
Get ATHE Alerts

News, Short Squeeze, Breakout and More Instantly...
ATHE - Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia

–   New Evidence Indicates ATH434 can Function as an Iron Chaperone to Redistribute Iron – MELBOURNE, Australia and SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company&#...
ATHE - Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

– ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson’s Disease – – ATH434-201 Phase 2 Baseline Data Confirm Approach to Target Biomarkers for Slowing Disease Progression – – 12-Month Data from bioMUSE ...

ATHE - BSGM, ENLV and WISA among mid-day movers

2024-04-15 12:47:11 ET More on Mid-day movers & stocks. Enlivex stock plunges 50% on mixed results from sepsis study WiSA Technologies to effect 1-for-150 reverse stock split Seeking Alpha’s Quant Rating on BioSig Technologies, Inc. Historical earn...

ATHE - NXPL, MGRM and OCX among pre-market losers

2024-04-15 08:21:07 ET More on Pre-market losers & stocks. OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript Monogram Orthopaedics, Inc. (MGRM) Q4 2023 Earnings Call Transcript Monogram Orthopaedics, Inc. 2023 Q4 - Results - Earnings Call Presentation ...
ATHE - ATUS, ATHE and GRFS among pre-market losers

2024-04-11 08:16:21 ET More on pre-market losers stock Grifols: Q4 Was Positive, Still Too Many Question Marks Altice USA: Recent Refinancing Buys Time But Challenges Remain Altice USA, Inc. (ATUS) Q4 2023 Earnings Call Transcript Altice slips as Wells Fargo ...

ATHE - Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024

MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today a...

ATHE - Alterity Therapeutics receives A$3.9M research & development tax incentive refund

2024-03-26 11:11:56 ET More on Alterity Therapeutics Alterity Therapeutics drops on capital raise Seeking Alpha’s Quant Rating on Alterity Therapeutics Historical earnings data for Alterity Therapeutics Financial information for Alterity Therapeutics ...
ATHE - Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund

MELBOURNE, Australia and SAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative...

ATHE - Alterity Therapeutics drops on capital raise

2024-02-23 13:39:42 ET More on Alterity Therapeutics Alterity jumps after promising data on Parkinson's candidate Seeking Alpha’s Quant Rating on Alterity Therapeutics Historical earnings data for Alterity Therapeutics Financial information for Alterit...

ATHE - Vir Biotechnology, Community Health Systems among healthcare movers

2024-02-23 10:00:17 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming UBS concedes it wasn't bullis...
Next 10